DAPTOMYCIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C72H101N17O26
Molecular Weight	1620.6706
Optical Activity	UNSPECIFIED
Defined Stereocenters	13 / 13
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]3[C@@H](C)OC(=O)[C@H](CC(=O)C4=CC=CC=C4N)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC3=O)[C@H](C)CC(O)=O

InChI

InChIKey=DOAKLVKFURWEDJ-QCMAZARJSA-N

InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35-,36-,37-,43+,44+,45-,46+,47+,48+,49+,50-,60+,61+/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021572s033lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.drugbank.ca/drugs/DB00080

Daptomycin is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by Gram-positive organisms. Daptomycin has a distinct mechanism of action, disrupting multiple aspects of bacterial cell membrane function. It inserts into the cell membrane in a phosphatidylglycerol-dependent fashion, where it then aggregates. The aggregation of daptomycin alters the curvature of the membrane, which creates holes that leak ions. This causes rapid depolarization, resulting in a loss of membrane potential leading to inhibition of protein, DNA, and RNA synthesis, which results in bacterial cell death. Daptomycin is bactericidal against Gram-positive bacteria only. It has proven in vitro activity against enterococci (including glycopeptide-resistant enterococci (GRE)), staphylococci (including methicillin-resistant Staphylococcus aureus), streptococci, corynebacteria and stationary-phase Borrelia burgdorferi persisters.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Staphylococcus aureus 67 Target ID: CHEMBL352 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Binding Agent 1064
Staphylococcus 2 Target ID: CHEMBL612624 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20176900	Binding Agent 1064

Conditions

Condition	Modality	Targets	Highest Phase	Product
Complicated skin and skin structure infections 11 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Curative		Approved 8429	CUBICIN Approved Use CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2) Launch Date 2003
Staphylococcus aureus bloodstream infections 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf	Curative		Approved 8429	CUBICIN Approved Use CUBICIN® is indicated for the treatment of the infections listed below. CUBICIN is a lipopeptide antibacterial indicated for the treatment of: Complicated skin and skin structure infections (cSSSI) (1.1) Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis (1.2) CUBICIN is not indicated for the treatment of pneumonia. (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN and other antibacterial drugs, CUBICIN should be used to treat infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections Complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive bacteria: Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Those with Right-Sided Infective Endocarditis, Caused by Methicillin-Susceptible and Methicillin-Resistant Isolates Staphylococcus aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates. 1.3 Limitations of Use CUBICIN is not indicated for the treatment of pneumonia. CUBICIN is not indicated for the treatment of left-sided infective endocarditis due to S. aureus. The clinical trial of CUBICIN in patients with S. aureus bloodstream infections included limited data from patients with left-sided infective endocarditis; outcomes in these patients were poor [see Clinical Trials (14.2) Launch Date 2003

C_max

Value	Dose	Analyte	Population
141.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
183.7 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
57.8 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
93.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
123.3 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59.1 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	6 mg/kg 1 times / day steady, intravenous dose: 6 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
92.3 ug/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	8 mg/kg 1 times / day steady, intravenous dose: 8 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:

AUC

Value	Dose	Analyte	Population
1039 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1277 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
494 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
632 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
858 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
499 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	6 mg/kg 1 times / day steady, intravenous dose: 6 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:
821 ug*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT00428844	8 mg/kg 1 times / day steady, intravenous dose: 8 mg/kg route of administration: intravenous experiment type: steady co-administered:	DAPTOMYCIN plasma	Homo sapiens population: unhealthy age: Adults sex: F+M food status:

T_1/2

Value	Dose	Analyte	Population
7.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	10 mg/kg 1 times / day steady-state, intravenous dose: 10 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.7 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	12 mg/kg 1 times / day steady-state, intravenous dose: 12 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.1 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7.9 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	6 mg/kg 1 times / day steady-state, intravenous dose: 6 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
8.3 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	8 mg/kg 1 times / day steady-state, intravenous dose: 8 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
8.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021572s059lbl.pdf	4 mg/kg 1 times / day steady-state, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered:		DAPTOMYCIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
10 mg/kg single, intravenous Highest studied dose Dose: 10 mg/kg Route: intravenous Route: single Dose: 10 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/	unhealthy, 2 - 6 years n = 6 Health Status: unhealthy Condition: bacterial infection Age Group: 2 - 6 years Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/	Sources: https://pubmed.ncbi.nlm.nih.gov/21317681/
6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	Disc. AE: Creatine kinase increased, Renal impairment... AEs leading to discontinuation/dose reduction: Creatine kinase increased (3 patients) Renal impairment (1 patient) Death (18 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
6 mg/kg single, intravenous Recommended Dose: 6 mg/kg Route: intravenous Route: single Dose: 6 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/	unhealthy, 3–24 Months Health Status: unhealthy Condition: proven/suspected bacterial infection Age Group: 3–24 Months Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/	Sources: https://pubmed.ncbi.nlm.nih.gov/25361023/
10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	Disc. AE: Cardiac failure, Hypocalcemia... AEs leading to discontinuation/dose reduction: Cardiac failure (4 patients) Hypocalcemia (grade 4, 1 patient) Acute renal failure (1 patient) Acute liver injury (1 patient) Gastrointestinal bleeding (1 patient) Nausea and vomiting (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years n = 81 Health Status: unhealthy Condition: bacterial infection Age Group: 62 - 80 years Sex: M+F Population Size: 81 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	Disc. AE: Acute renal failure, Respiratory failure... AEs leading to discontinuation/dose reduction: Acute renal failure (1 patient) Respiratory failure (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/

AEs

AE	Significance	Dose	Population
Renal impairment	1 patient Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Death	18 patients Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Creatine kinase increased	3 patients Disc. AE	6 mg/kg 1 times / day steady, intravenous Recommended Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/	unhealthy, 21 - 87 years n = 120 Health Status: unhealthy Condition: bacterial infection Age Group: 21 - 87 years Sex: M+F Population Size: 120 Sources: https://pubmed.ncbi.nlm.nih.gov/16914701/
Acute liver injury	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Acute renal failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Gastrointestinal bleeding	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Nausea and vomiting	2 patients Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Cardiac failure	4 patients Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Hypocalcemia	grade 4, 1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Co-administed with:: fosfomycin(2 g) Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 60.8 - 80.8 years n = 74 Health Status: unhealthy Condition: bacterial infection Age Group: 60.8 - 80.8 years Sex: M+F Population Size: 74 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Acute renal failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years n = 81 Health Status: unhealthy Condition: bacterial infection Age Group: 62 - 80 years Sex: M+F Population Size: 81 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/
Respiratory failure	1 patient Disc. AE	10 mg/kg 1 times / day steady, intravenous Recommended Dose: 10 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 10 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/	unhealthy, 62 - 80 years n = 81 Health Status: unhealthy Condition: bacterial infection Age Group: 62 - 80 years Sex: M+F Population Size: 81 Sources: https://pubmed.ncbi.nlm.nih.gov/32725216/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1587 inducer 781	inhibitor 1767 inducer 389	inhibitor 1852 inducer 97	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2A6 707 CYP2C19 1478 CYP2E1 882	P-gp 1537	CYP1A2 701 CYP2A6 79 CYP2C19 293 CYP2E1 128

Drug as perpetrator

Target	Modality	Activity
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP1A2 1692	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2A6 739	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2A6 739	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C19 1553	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2D6 1891	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2E1 970	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP3A4 1925	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely
CYP3A4 1925	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_BioPharmr_P1.pdf#page=8 Page: 8.0	unlikely

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1537	substrate 3367 Sources: https://academic.oup.com/jac/article/70/1/307/2911350	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-572_Cubicin_Pharmr.pdf#page=9 Page: 9.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:600103	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:600103
ChemicalBook	CB8855073	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8855073
MolPort	MolPort-003-846-138	https://www.molport.com/shop/molecule-link/MolPort-003-846-138
eMolecules	11312095	https://www.emolecules.com/cgi-bin/more?vid=11312095

PubMed

Title	Date	PubMed
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.	2003 May	12709345
Muscle pain associated with daptomycin.	2004 Nov	15367725
Successful treatment of Corynebacterium striatum endocarditis with daptomycin plus rifampin.	2005 Oct	16144879
Therapy-refractory Panton Valentine Leukocidin-positive community-acquired methicillin-sensitive Staphylococcus aureus sepsis with progressive metastatic soft tissue infection: a case report.	2007 Dec 3	18053175
Infective endocarditis caused by USA300 methicillin-resistant Staphylococcus aureus (MRSA).	2007 Jul	17428640
Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster.	2007 Nov 15	17968832
[New anti-Gram+antibiotics: which role in infective endocarditis?].	2008 Apr	18395180
Community-associated methicillin-resistant Staphylococcus aureus pyomyositis complicated by compartment syndrome in an immunocompetent young woman.	2008 Jul	18606349
Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis.	2008 May	18381844
Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy.	2008 May	18349306
Use of daptomycin in a pregnant patient with Staphylococcus aureus endocarditis.	2010 Apr	20197474
Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect").	2010 Aug	20547804
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

4 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min) 6 mg/kg once every 24 hours (every 48 hours if creatinine clearance <30 mL/min)

Route of Administration: Intravenous

In Vitro Use Guide

In vitro activities of daptomycin was studied against more than 100 strains each of Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. For 392 of 421 strains (93%), daptomycin was inhibitory at <1 g/ml,

Name

Type

Language

DAPTOMYCIN

Official Name

English

DAPTOMYCIN [MI]

Common Name

English

LY-146032

Code

English

CUBICIN

Brand Name

English

CIDECIN

Brand Name

English

DAPTOMYCIN [MART.]

Common Name

English

DAPTOMYCIN [ORANGE BOOK]

Common Name

English

daptomycin [INN]

Common Name

English

DAPZURA RT

Brand Name

English

LY 146032

Code

English

DAPTOMYCIN [USAN]

Common Name

English

DAPTOMYCIN [EMA EPAR]

Common Name

English

LY-164032

Code

English

N-DECANOYL-L-TRYPTOPHYL-L-ASPARAGINYL-L-ASPARTYL-L-THREONYLGLYCYL-L-ORNITHYL-L-ASPARTYL-D-ALANYL-L-ASPARTYLGLYCYL-D-SERYL-THREO-3-METHYL-L-GLUTAMYL-3-ANTHRANILOYL-L-ALANINE E1-LACTONE

Common Name

English

DAPTOMYCIN [JAN]

Common Name

English

Daptomycin [WHO-DD]

Common Name

English

DAPCIN

Brand Name

English

DAPTOMYCIN [VANDF]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175509